| Code | CSB-RA878862MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Navicixizumab, targeting Delta-like ligand 4 (DLL4), a critical transmembrane protein in the Notch signaling pathway. DLL4 is predominantly expressed on vascular endothelial cells and plays an essential role in regulating angiogenesis by controlling endothelial tip cell selection and vascular sprouting. Aberrant DLL4 expression has been implicated in tumor angiogenesis and cancer progression, as tumors exploit this pathway to establish blood supply networks that support their growth and metastasis. Elevated DLL4 levels have been observed in various solid tumors, including colorectal, ovarian, and lung cancers, making it an attractive target for anti-angiogenic therapeutic strategies.
Navixizumab is a type of IgG2 bispecific monoclonal antibody targeting DLL4/VEGF. It can simultaneously inhibit the VEGF and DLL4 signaling pathways, resulting in dysfunctional and inefficient tumor blood vessels, thereby cutting off the supply of nutrients and oxygen to the tumor and inhibiting tumor growth. This biosimilar antibody provides researchers with a valuable tool for investigating DLL4-mediated angiogenesis, tumor microenvironment dynamics, and Notch signaling mechanisms in oncology research. It supports studies exploring anti-angiogenic strategies and combination therapy approaches in preclinical cancer models.
There are currently no reviews for this product.